See Supplemental Patient Information
- Roflumilast should not be used for the relief of acute bronchospasm
- Therapy is associated with an increase in psychiatric adverse reactions such as insomnia, anxiety, depression, and instances of suicidal ideation and behavior, including completed suicide. Before initiating therapy, prescribers should carefully weigh the risks and benefits of treatment with roflumilast in patients with a history of depression and/or suicidal thoughts or behavior
- Weight loss has been reported in most patients treated with roflumilast; monitor weight regularly in such patients. Evaluate weight loss and consider discontinuation of therapy if unexplained or clinically significant weight loss occurs
- Concomitant use of strong CYP450 enzyme inducers such as rifampicin, phenobarbital, carbamazepine, and phenytoin is not recommended, as it may result in a reduced therapeutic effectiveness of roflumilast
Cautions: Use cautiously in
- Child-Pugh Class A hepatic impairment
- Hx of depression
- Suicidal ideation
- Smoking habit changes
Supplemental Patient Information
- Advise patients, their caregivers, and families of the need to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other mood changes and report any such changes to their healthcare provider
Pregnancy Category:C
Breastfeeding: Safety unknown. Manufacturer advises avoidance in nursing women.
Pricing data from www.DrugStore.com in U.S.A.
- Daliresp 500 MCG TABS [Bottle] (FOREST)
30 mcg = $199.98
90 mcg = $579.95
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
